IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Esperion Therapeutics Inc (ESPR)

CUSIP: 29664W105 | NYSE | Healthcare · Drug Manufacturers - Specialty & Generic | Small Cap | 846 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13GThe Goldman Sachs Group, Inc.17,222,1566.7%New 5%+ stakeJun 30, 2026No 13F filer matched
13GThe Goldman Sachs Group, Inc.17,222,156
6.7% of class · Jun 30, 2026New 5%+ stake
No 13F filer matched

Institutional Holders — Q3 2026

Asset Planning,Inc900
0.0% of portfolio›$0
StyleTurnoverLocationFiled
Asset Planning,Inc
900$00.0%CoreVery LowLos Alamitos, CA2026-10-26